Nigral glutathione deficiency is not specific for idiopathic Parkinson's disease
Identifieur interne : 002E43 ( Main/Curation ); précédent : 002E42; suivant : 002E44Nigral glutathione deficiency is not specific for idiopathic Parkinson's disease
Auteurs : Paul S. Fitzmaurice [Canada] ; Lee Ang [Canada] ; Mark Guttman [Canada] ; Ali H. Rajput [Canada] ; Yoshiaki Furukawa [Canada] ; Stephen J. Kish [Canada]Source :
- Movement Disorders [ 0885-3185 ] ; 2003-09.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Analyse quantitative, Homme.
English descriptors
- KwdEn :
- Aged, Antioxidants (metabolism), Comparative study, Glutathione, Glutathione (deficiency), Human, Humans, Idiopathic, Locus niger, Multiple System Atrophy (metabolism), Multiple system atrophy, Oxidative Stress, Oxidative stress, Parkinson Disease (metabolism), Parkinson disease, Parkinson's disease, Pathogenesis, Quantitative analysis, Substantia Nigra (metabolism), Supranuclear Palsy, Progressive (metabolism), Supranuclear ophthalmoplegia, Uric Acid (metabolism), glutathione, multiple system atrophy, oxidative stress, progressive supranuclear palsy, substantia nigra.
- MESH :
- chemical , deficiency : Glutathione.
- chemical , metabolism : Antioxidants, Uric Acid.
- metabolism : Multiple System Atrophy, Parkinson Disease, Substantia Nigra, Supranuclear Palsy, Progressive.
- Aged, Humans, Oxidative Stress.
Abstract
The consistent findings of decreased levels of the major antioxidant glutathione in substantia nigra of patients with idiopathic Parkinson's disease (PD) has provided most of the basis for the oxidative stress hypothesis of the etiology of PD. To establish whether a nigral glutathione deficiency is unique to PD, as is generally assumed, or is present in other Parkinsonian conditions associated with nigral damage, we compared levels of reduced glutathione (GSH) in postmortem brain of patients with PD to those with progressive supranuclear palsy (PSP) and multiple system atrophy (MSA). As compared with the controls, nigral GSH levels were decreased in the PD and PSP patient groups (P < 0.05 for PD [−30%], PSP [−21%]), whereas a similar decrease in the MSA patient group did not reach statistical significance (P = 0.078, MSA [−20%]). GSH levels were normal in all examined normal and degenerating extra‐nigral brain areas in PSP and MSA. A trend for decreased levels of uric acid (antioxidant and product of purine catabolism) also was observed in nigra of all patient groups (−19 to −30%). These data suggest that glutathione depletion, possibly consequent to overutilisation in oxidative stress reactions, could play a causal role in nigral degeneration in all nigrostriatal dopamine deficiency disorders, and that antioxidant therapeutic approaches should not be restricted to PD. © 2003 Movement Disorder Society
Url:
DOI: 10.1002/mds.10486
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001F64
- to stream Istex, to step Curation: Pour aller vers cette notice dans l'étape Curation :001F64
- to stream Istex, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :000E46
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001419
- to stream PubMed, to step Curation: Pour aller vers cette notice dans l'étape Curation :001419
- to stream PubMed, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :001419
- to stream Ncbi, to step Merge: Pour aller vers cette notice dans l'étape Curation :000352
- to stream Ncbi, to step Curation: Pour aller vers cette notice dans l'étape Curation :000352
- to stream Ncbi, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :000352
- to stream Main, to step Merge: Pour aller vers cette notice dans l'étape Curation :003241
- to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000A32
- to stream PascalFrancis, to step Curation: Pour aller vers cette notice dans l'étape Curation :000291
- to stream PascalFrancis, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :000935
- to stream Main, to step Merge: Pour aller vers cette notice dans l'étape Curation :003321
Links to Exploration step
ISTEX:57555A8D09E20110590BCE420F0B37968371034DLe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Nigral glutathione deficiency is not specific for idiopathic Parkinson's disease</title>
<author><name sortKey="Fitzmaurice, Paul S" sort="Fitzmaurice, Paul S" uniqKey="Fitzmaurice P" first="Paul S." last="Fitzmaurice">Paul S. Fitzmaurice</name>
</author>
<author><name sortKey="Ang, Lee" sort="Ang, Lee" uniqKey="Ang L" first="Lee" last="Ang">Lee Ang</name>
</author>
<author><name sortKey="Guttman, Mark" sort="Guttman, Mark" uniqKey="Guttman M" first="Mark" last="Guttman">Mark Guttman</name>
</author>
<author><name sortKey="Rajput, Ali H" sort="Rajput, Ali H" uniqKey="Rajput A" first="Ali H." last="Rajput">Ali H. Rajput</name>
</author>
<author><name sortKey="Furukawa, Yoshiaki" sort="Furukawa, Yoshiaki" uniqKey="Furukawa Y" first="Yoshiaki" last="Furukawa">Yoshiaki Furukawa</name>
</author>
<author><name sortKey="Kish, Stephen J" sort="Kish, Stephen J" uniqKey="Kish S" first="Stephen J." last="Kish">Stephen J. Kish</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:57555A8D09E20110590BCE420F0B37968371034D</idno>
<date when="2003" year="2003">2003</date>
<idno type="doi">10.1002/mds.10486</idno>
<idno type="url">https://api-v5.istex.fr/document/57555A8D09E20110590BCE420F0B37968371034D/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">001F64</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001F64</idno>
<idno type="wicri:Area/Istex/Curation">001F64</idno>
<idno type="wicri:Area/Istex/Checkpoint">000E46</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000E46</idno>
<idno type="wicri:doubleKey">0885-3185:2003:Fitzmaurice P:nigral:glutathione:deficiency</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:14502663</idno>
<idno type="wicri:Area/PubMed/Corpus">001419</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001419</idno>
<idno type="wicri:Area/PubMed/Curation">001419</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001419</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001419</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001419</idno>
<idno type="wicri:Area/Ncbi/Merge">000352</idno>
<idno type="wicri:Area/Ncbi/Curation">000352</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000352</idno>
<idno type="wicri:doubleKey">0885-3185:2003:Fitzmaurice P:nigral:glutathione:deficiency</idno>
<idno type="wicri:Area/Main/Merge">003241</idno>
<idno type="wicri:source">INIST</idno>
<idno type="RBID">Pascal:04-0053700</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000A32</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000291</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000935</idno>
<idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000935</idno>
<idno type="wicri:doubleKey">0885-3185:2003:Fitzmaurice P:nigral:glutathione:deficiency</idno>
<idno type="wicri:Area/Main/Merge">003321</idno>
<idno type="wicri:Area/Main/Curation">002E43</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Nigral glutathione deficiency is not specific for idiopathic Parkinson's disease</title>
<author><name sortKey="Fitzmaurice, Paul S" sort="Fitzmaurice, Paul S" uniqKey="Fitzmaurice P" first="Paul S." last="Fitzmaurice">Paul S. Fitzmaurice</name>
<affiliation wicri:level="1"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Human Neurochemical Pathology Laboratory, Centre for Addiction and Mental Health, Toronto, Ontario</wicri:regionArea>
<wicri:noRegion>Ontario</wicri:noRegion>
</affiliation>
<affiliation></affiliation>
</author>
<author><name sortKey="Ang, Lee" sort="Ang, Lee" uniqKey="Ang L" first="Lee" last="Ang">Lee Ang</name>
<affiliation wicri:level="1"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Division of Neuropathology, London Health Science Centre, University of Western Ontario, London, Ontario</wicri:regionArea>
<wicri:noRegion>Ontario</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Guttman, Mark" sort="Guttman, Mark" uniqKey="Guttman M" first="Mark" last="Guttman">Mark Guttman</name>
<affiliation wicri:level="1"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Human Neurochemical Pathology Laboratory, Centre for Addiction and Mental Health, Toronto, Ontario</wicri:regionArea>
<wicri:noRegion>Ontario</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Rajput, Ali H" sort="Rajput, Ali H" uniqKey="Rajput A" first="Ali H." last="Rajput">Ali H. Rajput</name>
<affiliation wicri:level="1"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Division of Neurology, University of Saskatchewan, Saskatoon, Saskatchewan</wicri:regionArea>
<wicri:noRegion>Saskatchewan</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Furukawa, Yoshiaki" sort="Furukawa, Yoshiaki" uniqKey="Furukawa Y" first="Yoshiaki" last="Furukawa">Yoshiaki Furukawa</name>
<affiliation wicri:level="1"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Movement Disorders Research Laboratory, Centre for Addiction and Mental Health, Toronto, Ontario</wicri:regionArea>
<wicri:noRegion>Ontario</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Kish, Stephen J" sort="Kish, Stephen J" uniqKey="Kish S" first="Stephen J." last="Kish">Stephen J. Kish</name>
<affiliation wicri:level="1"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Human Neurochemical Pathology Laboratory, Centre for Addiction and Mental Health, Toronto, Ontario</wicri:regionArea>
<wicri:noRegion>Ontario</wicri:noRegion>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="sub">Official Journal of the Movement Disorder Society</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2003-09">2003-09</date>
<biblScope unit="volume">18</biblScope>
<biblScope unit="issue">9</biblScope>
<biblScope unit="page" from="969">969</biblScope>
<biblScope unit="page" to="976">976</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">57555A8D09E20110590BCE420F0B37968371034D</idno>
<idno type="DOI">10.1002/mds.10486</idno>
<idno type="ArticleID">MDS10486</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term>
<term>Antioxidants (metabolism)</term>
<term>Comparative study</term>
<term>Glutathione</term>
<term>Glutathione (deficiency)</term>
<term>Human</term>
<term>Humans</term>
<term>Idiopathic</term>
<term>Locus niger</term>
<term>Multiple System Atrophy (metabolism)</term>
<term>Multiple system atrophy</term>
<term>Oxidative Stress</term>
<term>Oxidative stress</term>
<term>Parkinson Disease (metabolism)</term>
<term>Parkinson disease</term>
<term>Parkinson's disease</term>
<term>Pathogenesis</term>
<term>Quantitative analysis</term>
<term>Substantia Nigra (metabolism)</term>
<term>Supranuclear Palsy, Progressive (metabolism)</term>
<term>Supranuclear ophthalmoplegia</term>
<term>Uric Acid (metabolism)</term>
<term>glutathione</term>
<term>multiple system atrophy</term>
<term>oxidative stress</term>
<term>progressive supranuclear palsy</term>
<term>substantia nigra</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="deficiency" xml:lang="en"><term>Glutathione</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Antioxidants</term>
<term>Uric Acid</term>
</keywords>
<keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Multiple System Atrophy</term>
<term>Parkinson Disease</term>
<term>Substantia Nigra</term>
<term>Supranuclear Palsy, Progressive</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Aged</term>
<term>Humans</term>
<term>Oxidative Stress</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Analyse quantitative</term>
<term>Atrophie multisystématisée</term>
<term>Etude comparative</term>
<term>Glutathion</term>
<term>Homme</term>
<term>Idiopathique</term>
<term>Locus niger</term>
<term>Ophtalmoplégie supranucléaire</term>
<term>Parkinson maladie</term>
<term>Pathogénie</term>
<term>Stress oxydatif</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Analyse quantitative</term>
<term>Homme</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The consistent findings of decreased levels of the major antioxidant glutathione in substantia nigra of patients with idiopathic Parkinson's disease (PD) has provided most of the basis for the oxidative stress hypothesis of the etiology of PD. To establish whether a nigral glutathione deficiency is unique to PD, as is generally assumed, or is present in other Parkinsonian conditions associated with nigral damage, we compared levels of reduced glutathione (GSH) in postmortem brain of patients with PD to those with progressive supranuclear palsy (PSP) and multiple system atrophy (MSA). As compared with the controls, nigral GSH levels were decreased in the PD and PSP patient groups (P < 0.05 for PD [−30%], PSP [−21%]), whereas a similar decrease in the MSA patient group did not reach statistical significance (P = 0.078, MSA [−20%]). GSH levels were normal in all examined normal and degenerating extra‐nigral brain areas in PSP and MSA. A trend for decreased levels of uric acid (antioxidant and product of purine catabolism) also was observed in nigra of all patient groups (−19 to −30%). These data suggest that glutathione depletion, possibly consequent to overutilisation in oxidative stress reactions, could play a causal role in nigral degeneration in all nigrostriatal dopamine deficiency disorders, and that antioxidant therapeutic approaches should not be restricted to PD. © 2003 Movement Disorder Society</div>
</front>
</TEI>
<double idat="0885-3185:2003:Fitzmaurice P:nigral:glutathione:deficiency"><INIST><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Nigral glutathione deficiency is not specific for idiopathic Parkinson's disease</title>
<author><name sortKey="Fitzmaurice, Paul S" sort="Fitzmaurice, Paul S" uniqKey="Fitzmaurice P" first="Paul S." last="Fitzmaurice">Paul S. Fitzmaurice</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Human Neurochemical Pathology Laboratory, Centre for Addiction and Mental Health</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Toronto, Ontario</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Lee Ang" sort="Lee Ang" uniqKey="Lee Ang" last="Lee Ang">LEE ANG</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Division of Neuropathology, London Health Science Centre, University of Western Ontario</s1>
<s2>London, Ontario</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>London, Ontario</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Guttman, Mark" sort="Guttman, Mark" uniqKey="Guttman M" first="Mark" last="Guttman">Mark Guttman</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Human Neurochemical Pathology Laboratory, Centre for Addiction and Mental Health</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Toronto, Ontario</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Rajput, Ali H" sort="Rajput, Ali H" uniqKey="Rajput A" first="Ali H." last="Rajput">Ali H. Rajput</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Division of Neurology, University of Saskatchewan</s1>
<s2>Saskatoon, Saskatchewan</s2>
<s3>CAN</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Saskatoon, Saskatchewan</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Furukawa, Yoshiaki" sort="Furukawa, Yoshiaki" uniqKey="Furukawa Y" first="Yoshiaki" last="Furukawa">Yoshiaki Furukawa</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Movement Disorders Research Laboratory, Centre for Addiction and Mental Health</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Toronto, Ontario</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Kish, Stephen J" sort="Kish, Stephen J" uniqKey="Kish S" first="Stephen J." last="Kish">Stephen J. Kish</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Human Neurochemical Pathology Laboratory, Centre for Addiction and Mental Health</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Toronto, Ontario</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">04-0053700</idno>
<date when="2003">2003</date>
<idno type="stanalyst">PASCAL 04-0053700 INIST</idno>
<idno type="RBID">Pascal:04-0053700</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000A32</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000291</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000935</idno>
<idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000935</idno>
<idno type="wicri:doubleKey">0885-3185:2003:Fitzmaurice P:nigral:glutathione:deficiency</idno>
<idno type="wicri:Area/Main/Merge">003321</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Nigral glutathione deficiency is not specific for idiopathic Parkinson's disease</title>
<author><name sortKey="Fitzmaurice, Paul S" sort="Fitzmaurice, Paul S" uniqKey="Fitzmaurice P" first="Paul S." last="Fitzmaurice">Paul S. Fitzmaurice</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Human Neurochemical Pathology Laboratory, Centre for Addiction and Mental Health</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Toronto, Ontario</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Lee Ang" sort="Lee Ang" uniqKey="Lee Ang" last="Lee Ang">LEE ANG</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Division of Neuropathology, London Health Science Centre, University of Western Ontario</s1>
<s2>London, Ontario</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>London, Ontario</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Guttman, Mark" sort="Guttman, Mark" uniqKey="Guttman M" first="Mark" last="Guttman">Mark Guttman</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Human Neurochemical Pathology Laboratory, Centre for Addiction and Mental Health</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Toronto, Ontario</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Rajput, Ali H" sort="Rajput, Ali H" uniqKey="Rajput A" first="Ali H." last="Rajput">Ali H. Rajput</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Division of Neurology, University of Saskatchewan</s1>
<s2>Saskatoon, Saskatchewan</s2>
<s3>CAN</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Saskatoon, Saskatchewan</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Furukawa, Yoshiaki" sort="Furukawa, Yoshiaki" uniqKey="Furukawa Y" first="Yoshiaki" last="Furukawa">Yoshiaki Furukawa</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Movement Disorders Research Laboratory, Centre for Addiction and Mental Health</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Toronto, Ontario</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Kish, Stephen J" sort="Kish, Stephen J" uniqKey="Kish S" first="Stephen J." last="Kish">Stephen J. Kish</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Human Neurochemical Pathology Laboratory, Centre for Addiction and Mental Health</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Toronto, Ontario</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2003">2003</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Comparative study</term>
<term>Glutathione</term>
<term>Human</term>
<term>Idiopathic</term>
<term>Locus niger</term>
<term>Multiple system atrophy</term>
<term>Oxidative stress</term>
<term>Parkinson disease</term>
<term>Pathogenesis</term>
<term>Quantitative analysis</term>
<term>Supranuclear ophthalmoplegia</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Parkinson maladie</term>
<term>Idiopathique</term>
<term>Atrophie multisystématisée</term>
<term>Glutathion</term>
<term>Analyse quantitative</term>
<term>Ophtalmoplégie supranucléaire</term>
<term>Locus niger</term>
<term>Stress oxydatif</term>
<term>Etude comparative</term>
<term>Pathogénie</term>
<term>Homme</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Analyse quantitative</term>
<term>Homme</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The consistent findings of decreased levels of the major antioxidant glutathione in substantia nigra of patients with idiopathic Parkinson's disease (PD) has provided most of the basis for the oxidative stress hypothesis of the etiology of PD. To establish whether a nigral glutathione deficiency is unique to PD, as is generally assumed, or is present in other Parkinsonian conditions associated with nigral damage, we compared levels of reduced glutathione (GSH) in postmortem brain of patients with PD to those with progressive supranuclear palsy (PSP) and multiple system atrophy (MSA). As compared with the controls, nigral GSH levels were decreased in the PD and PSP patient groups (P < 0.05 for PD [-30%], PSP [-21%]), whereas a similar decrease in the MSA patient group did not reach statistical significance (P = 0.078, MSA [-20%]). GSH levels were normal in all examined normal and degenerating extra-nigral brain areas in PSP and MSA. A trend for decreased levels of uric acid (antioxidant and product of purine catabolism) also was observed in nigra of all patient groups (-19 to -30%). These data suggest that glutathione depletion, possibly consequent to overutilisation in oxidative stress reactions, could play a causal role in nigral degeneration in all nigrostriatal dopamine deficiency disorders, and that antioxidant therapeutic approaches should not be restricted to PD.</div>
</front>
</TEI>
</INIST>
<ISTEX><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Nigral glutathione deficiency is not specific for idiopathic Parkinson's disease</title>
<author><name sortKey="Fitzmaurice, Paul S" sort="Fitzmaurice, Paul S" uniqKey="Fitzmaurice P" first="Paul S." last="Fitzmaurice">Paul S. Fitzmaurice</name>
</author>
<author><name sortKey="Ang, Lee" sort="Ang, Lee" uniqKey="Ang L" first="Lee" last="Ang">Lee Ang</name>
</author>
<author><name sortKey="Guttman, Mark" sort="Guttman, Mark" uniqKey="Guttman M" first="Mark" last="Guttman">Mark Guttman</name>
</author>
<author><name sortKey="Rajput, Ali H" sort="Rajput, Ali H" uniqKey="Rajput A" first="Ali H." last="Rajput">Ali H. Rajput</name>
</author>
<author><name sortKey="Furukawa, Yoshiaki" sort="Furukawa, Yoshiaki" uniqKey="Furukawa Y" first="Yoshiaki" last="Furukawa">Yoshiaki Furukawa</name>
</author>
<author><name sortKey="Kish, Stephen J" sort="Kish, Stephen J" uniqKey="Kish S" first="Stephen J." last="Kish">Stephen J. Kish</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:57555A8D09E20110590BCE420F0B37968371034D</idno>
<date when="2003" year="2003">2003</date>
<idno type="doi">10.1002/mds.10486</idno>
<idno type="url">https://api-v5.istex.fr/document/57555A8D09E20110590BCE420F0B37968371034D/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">001F64</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001F64</idno>
<idno type="wicri:Area/Istex/Curation">001F64</idno>
<idno type="wicri:Area/Istex/Checkpoint">000E46</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000E46</idno>
<idno type="wicri:doubleKey">0885-3185:2003:Fitzmaurice P:nigral:glutathione:deficiency</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:14502663</idno>
<idno type="wicri:Area/PubMed/Corpus">001419</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001419</idno>
<idno type="wicri:Area/PubMed/Curation">001419</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001419</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001419</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001419</idno>
<idno type="wicri:Area/Ncbi/Merge">000352</idno>
<idno type="wicri:Area/Ncbi/Curation">000352</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000352</idno>
<idno type="wicri:doubleKey">0885-3185:2003:Fitzmaurice P:nigral:glutathione:deficiency</idno>
<idno type="wicri:Area/Main/Merge">003241</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Nigral glutathione deficiency is not specific for idiopathic Parkinson's disease</title>
<author><name sortKey="Fitzmaurice, Paul S" sort="Fitzmaurice, Paul S" uniqKey="Fitzmaurice P" first="Paul S." last="Fitzmaurice">Paul S. Fitzmaurice</name>
<affiliation wicri:level="1"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Human Neurochemical Pathology Laboratory, Centre for Addiction and Mental Health, Toronto, Ontario</wicri:regionArea>
<wicri:noRegion>Ontario</wicri:noRegion>
</affiliation>
<affiliation></affiliation>
</author>
<author><name sortKey="Ang, Lee" sort="Ang, Lee" uniqKey="Ang L" first="Lee" last="Ang">Lee Ang</name>
<affiliation wicri:level="1"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Division of Neuropathology, London Health Science Centre, University of Western Ontario, London, Ontario</wicri:regionArea>
<wicri:noRegion>Ontario</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Guttman, Mark" sort="Guttman, Mark" uniqKey="Guttman M" first="Mark" last="Guttman">Mark Guttman</name>
<affiliation wicri:level="1"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Human Neurochemical Pathology Laboratory, Centre for Addiction and Mental Health, Toronto, Ontario</wicri:regionArea>
<wicri:noRegion>Ontario</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Rajput, Ali H" sort="Rajput, Ali H" uniqKey="Rajput A" first="Ali H." last="Rajput">Ali H. Rajput</name>
<affiliation wicri:level="1"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Division of Neurology, University of Saskatchewan, Saskatoon, Saskatchewan</wicri:regionArea>
<wicri:noRegion>Saskatchewan</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Furukawa, Yoshiaki" sort="Furukawa, Yoshiaki" uniqKey="Furukawa Y" first="Yoshiaki" last="Furukawa">Yoshiaki Furukawa</name>
<affiliation wicri:level="1"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Movement Disorders Research Laboratory, Centre for Addiction and Mental Health, Toronto, Ontario</wicri:regionArea>
<wicri:noRegion>Ontario</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Kish, Stephen J" sort="Kish, Stephen J" uniqKey="Kish S" first="Stephen J." last="Kish">Stephen J. Kish</name>
<affiliation wicri:level="1"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Human Neurochemical Pathology Laboratory, Centre for Addiction and Mental Health, Toronto, Ontario</wicri:regionArea>
<wicri:noRegion>Ontario</wicri:noRegion>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="sub">Official Journal of the Movement Disorder Society</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2003-09">2003-09</date>
<biblScope unit="volume">18</biblScope>
<biblScope unit="issue">9</biblScope>
<biblScope unit="page" from="969">969</biblScope>
<biblScope unit="page" to="976">976</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">57555A8D09E20110590BCE420F0B37968371034D</idno>
<idno type="DOI">10.1002/mds.10486</idno>
<idno type="ArticleID">MDS10486</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term>
<term>Antioxidants (metabolism)</term>
<term>Glutathione (deficiency)</term>
<term>Humans</term>
<term>Multiple System Atrophy (metabolism)</term>
<term>Oxidative Stress</term>
<term>Parkinson Disease (metabolism)</term>
<term>Parkinson's disease</term>
<term>Substantia Nigra (metabolism)</term>
<term>Supranuclear Palsy, Progressive (metabolism)</term>
<term>Uric Acid (metabolism)</term>
<term>glutathione</term>
<term>multiple system atrophy</term>
<term>oxidative stress</term>
<term>progressive supranuclear palsy</term>
<term>substantia nigra</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="deficiency" xml:lang="en"><term>Glutathione</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Antioxidants</term>
<term>Uric Acid</term>
</keywords>
<keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Multiple System Atrophy</term>
<term>Parkinson Disease</term>
<term>Substantia Nigra</term>
<term>Supranuclear Palsy, Progressive</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Aged</term>
<term>Humans</term>
<term>Oxidative Stress</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The consistent findings of decreased levels of the major antioxidant glutathione in substantia nigra of patients with idiopathic Parkinson's disease (PD) has provided most of the basis for the oxidative stress hypothesis of the etiology of PD. To establish whether a nigral glutathione deficiency is unique to PD, as is generally assumed, or is present in other Parkinsonian conditions associated with nigral damage, we compared levels of reduced glutathione (GSH) in postmortem brain of patients with PD to those with progressive supranuclear palsy (PSP) and multiple system atrophy (MSA). As compared with the controls, nigral GSH levels were decreased in the PD and PSP patient groups (P < 0.05 for PD [−30%], PSP [−21%]), whereas a similar decrease in the MSA patient group did not reach statistical significance (P = 0.078, MSA [−20%]). GSH levels were normal in all examined normal and degenerating extra‐nigral brain areas in PSP and MSA. A trend for decreased levels of uric acid (antioxidant and product of purine catabolism) also was observed in nigra of all patient groups (−19 to −30%). These data suggest that glutathione depletion, possibly consequent to overutilisation in oxidative stress reactions, could play a causal role in nigral degeneration in all nigrostriatal dopamine deficiency disorders, and that antioxidant therapeutic approaches should not be restricted to PD. © 2003 Movement Disorder Society</div>
</front>
</TEI>
</ISTEX>
</double>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Main/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002E43 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Curation/biblio.hfd -nk 002E43 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Canada |area= ParkinsonCanadaV1 |flux= Main |étape= Curation |type= RBID |clé= ISTEX:57555A8D09E20110590BCE420F0B37968371034D |texte= Nigral glutathione deficiency is not specific for idiopathic Parkinson's disease }}
This area was generated with Dilib version V0.6.29. |